(Q33394597)

26 July 2017

title

Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients (English)

1 reference

26 July 2017

1 reference

Parameswaran Venugopal

object named as

Parameswaran Venugopal

9

0 references

author name string

Chadi Nabhan

1

1 reference

26 July 2017

Nancy Davis

2

1 reference

26 July 2017

Jacob D Bitran

3

1 reference

26 July 2017

Angel Galvez

4

1 reference

26 July 2017

Walter Fried

5

1 reference

26 July 2017

Kathy Tolzien

6

1 reference

26 July 2017

Susan Foss

7

1 reference

26 July 2017

Wendy M Dewey

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

8 November 2010

1 reference

26 July 2017

1 reference

26 July 2017

volume

117

1 reference

26 July 2017

issue

7

1 reference

26 July 2017

page(s)

1490-1497

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

Clofarabine: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

Mechanisms of anti-cancer action and pharmacology of clofarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

7 January 2021

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

7 January 2021

How I treat patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

7 January 2021

How I treat indolent lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

7 January 2021

Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

7 January 2021

Clofarabine in relapsed lymphoma: what is the optimal dose?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

7 January 2021

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25603

7 January 2021

Identifiers

DOI

10.1002/CNCR.25603

1 reference

release_ouasqgrx6rhxddxmh2tekqiujm

26 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ouasqgrx6rhxddxmh2tekqiujm

24 November 2022

mapped directly with Wikidata item

1 reference